Eli Lilly and Incyte's Olumiant has secured the first FDA approval for a systemic drug to treat alopecia areata, an autoimmune condition causing patchy hair loss that affects more than 700,000 ...

While similarities exist between types of alopecia, distinct clinical characteristics help patients & physicians ...

Discover management strategies for alopecia areata, from anti-inflammatory diets to stress reduction techniques that can help ...

Baricitinib, a once-daily, oral JAK inhibitor, is already approved under the brand name Olumiant to treat adult patients with ...

Pfizer has picked up approval in the EU for Litfulo, its JAK inhibitor for severe alopecia areata, extending its challenge to Eli Lilly’s first-to-market Olumiant. The European Commission has ...

The Food and Drug Administration has granted Fast Track designation to bempikibart for the treatment of alopecia areata.

Two JAK inhibitors were recently approved by the United States Food and Drug Administration for severe alopecia areata. Baricitinib, or Olumiant (Eli Lilly/Incyte), was approved for severe ...

These medications are dosed once daily. Baricitinib, or Olumiant, is available in 2 mg or 4 mg per day doses, again, for severe alopecia areata in adults 18 years of age and up. And ritlecitinib ...

Significant unmet needs were found among high-quality validation studies on the internal structure of patient-reported ...

Leqselvi, which also goes by the generic moniker deuruxolitinib, won an FDA green light to treat adults with severe alopecia areata last ... royalties from Lilly on Olumiant—also a JAK inhibitor ...